Gene therapy has emerged as a promising therapeutic strategy for various conditions, including blood disorders, ocular disease, cancer, and nervous system disorders. The advent of gene editing techniques has facilitated the ability of researchers to specifically target and modify the eukaryotic cell genome, making it a valuable tool for gene therapy. This can be performed through either in vivo or ex vivo approaches. Gene editing tools, such as zinc finger nucleases, transcription activator-like effector nucleases, and CRISPR-Cas-associated nucleases, can be employed for gene therapy purposes. Among these tools, CRISPR-Cas-based gene editing stands out because of its ability to introduce heritable genome changes by designing short guide RNAs. This review aims to provide an overview of CRISPR-Cas technology and summarizes the latest research on the application of CRISPR/Cas9 genome editing technology for the treatment of the most prevalent neurodegenerative diseases including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, Amyotrophic lateral sclerosis, and Spinocerebellar ataxia.
1 January 2008 in World Journal of Gastroenterology
Objective: In this study we aimed to assess anorexigenic peptide levels in patients with or without polycystic ovary syndrome (PCOS) and their effects on assisted reproductive treatment (ART) outcomes. Methods: A prospective case-control study was conducted in a tertiary care university-based ART clinic. Eighty-three patients were included in the study. The PCOS group included 41 patients, and the non-PCOS group included 42 controls. The 2003 Rotterdam criteria were used for PCOS patient selection. The ART indications in the non-PCOS group were tubal factor or unexplained infertility. Venous blood samples were taken on the third day of the menstrual cycle to determine the serum anorexigenic peptide levels. The enzyme-linked immunosorbent assay method was used for laboratory analyses. Results: In the PCOS group, serum obestatin levels were significantly lower than in the control group, but serum anorexigenic peptide levels were similar in PCOS patients with or without clinical pregnancy. Ovarian hyperstimulation syndrome (OHSS) was diagnosed only in PCOS patients, and the obestatin levels of OHSS patients were significantly lower than those of other PCOS patients. Conclusions: Baseline anorexigenic peptide levels did not affect the clinical pregnancy rate in ART cycles. Obestatin may play a role in the pathophysiology of OHSS; this possibility should be confirmed in further research.
Objectives: This study aims to demonstrate that proteolytic enzymes released as a result of hemolysis decrease the small peptide hormones, whereas N-phenyl maleimide (NPM) can be used to prevent hemolysis interference. Methods: The serum/plasma pools were prepared at two different concentrations and divided into two equal volumes. NPM solution was added to one sample. The erythrocyte package was washed five times and then centrifuged after each wash. Hemolysis was induced by the osmotic shock method upon adding distilled water. 100 µL of hemolysate stock solutions were added over 400 µL of serum/plasma pool. Repeated five times. Results: Negative interference was demonstrated on ACTH at 200 hemolysis index (HI) for low concentration, at 100 HI and 200 HI for high concentration, and insulin at 100 HI and 200 HI for high concentration. Addition of NPM which inactivates protease enzymes prevented the reduction of ACTH and insulin. No interference was observed at C-peptide and IGF-1 concentration until 200 HI. Conclusions: Hemolysis was detected to degrade ACTH and insulin, which demonstrated how important the effect of hemolysis can be utilized in deciding whether to accept or reject samples. The addition of NPM can increase accuracy in clinical decisions as well as treatment.